Amlodipine/telmisartan/hydrochlorothiazide - Boehringer Ingelheim/Astellas Pharma

Drug Profile

Amlodipine/telmisartan/hydrochlorothiazide - Boehringer Ingelheim/Astellas Pharma

Alternative Names: Amlodipine besylate/telmisartan/hydrochlorothiazide; Amlodipine/hydrochlorothiazide/telmisartan; Hydrochlorothiazide/amlodipine/telmisartan; Hydrochlorothiazide/telmisartan/amlodipine; Micatrio; Telmisartan/amlodipine/hydrochlorothiazide; Telmisartan/hydrochlorothiazide/amlodipine

Latest Information Update: 23 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Boehringer Ingelheim
  • Developer Astellas Pharma; Boehringer Ingelheim
  • Class Antihypertensives; Benzimidazoles; Benzoates; Benzothiadiazines; Branched-chain amino acids; Dihydropyridines; Small molecules
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists; Thiazide diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 18 Nov 2016 Launched for Hypertension in Japan (PO)
  • 28 Sep 2016 Registered for Hypertension in Japan (PO)
  • 07 Jan 2016 Boehringer Ingelheim and Astellas Pharma extend agreement related to sale and co-promotion of telmisartan/hydrochlorothiazide (Micardis® family) in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top